73% in a Week Riding the Biotech Comeback – Here’s What’s Next

Biotech is one of the most potentially lucrative yet endlessly frustrating market sectors.

Last year was particularly annoying. There were a couple big wins in the space, but the entire industry has been kneecapped for a few reasons…

• First, the post-COVID hangover is still there, and it’s tough to get patients for testing. 
• Second, the cost per pharma patient is between $30,000- $70,000 each. (I learned that at a healthcare conference last year.)
• Third, interest rates are still too damn high. 
• And fourth, no one knows what’s going to happen with the Trump administration and Big Pharma. 

But all of that is in the rearview mirror now – and with that narrative getting priced in, it’s time to start looking at biotech as a viable space again…

And BridgeBio (BBIO) is leading the way.

The Biotech Comeback Is Just Getting Started

In early January I noticed two things:

First, BBIO was trading near its range highs while the rest of the biotech space was getting clobbered. 

That told me there was a “strange bid” in the stock that required further digging. 

Second, the chart had built out a Point of Control (POC) at the upper end of that range. That tells me there is some urgency in the name and if the stock managed to clear above it, it was going to push higher. 

That’s why I alerted our paid clients to purchase the stock at $29.38, and we’re up a quick 15% in a week. 

I also recommended the Jul $40 call option, which is trading as I write this at $3.45. When we alerted our clients,  it was trading at $2.00, so that’s a 72.5% gain in the same time period – and I’m expecting more after this pullback finishes. 

Of course, biotech is only one sector we’re exploiting with this POC strategy…

Click here and I’ll show you how we’ve used it to find wins like 158%, 433%, and 503% in a free training video. 

Original Post Can be Found Here